POPULARITY
Greenland is holding a general election on Wednesday. It's a semi-autonomous part of Denmark and independence is a major issue - particularly after U.S President Donald Trump expressed interest in controlling the world's biggest island. Denmark correspondent Matthew Harrison spoke to Ingrid Hipkiss.
20250228 In Perspective Originally Broadcasted February 28, 2025, on ACB Media 5 This episode featured Dr Kerri Brackney and Dr Matthew Harrison, American Association of Pro-Life OB GYNs. Sponsored by: Branco Events Find out more at https://acb-community.pinecast.co
We believe, teach, and confess the Book of Concord because it is in accord with the Word of God. It is vital that the Church still confess this Truth today, as it leaves us no wiggle room to invent our own ideas. The authority for this is founded in the Divine Scriptures as Jesus tells us, “You will know the Truth and the Truth will set you free (John 8:32).” The Concordians were not writing to create a general guide to the Bible, but because they believed that these writings were the true Word of God! “O Lord, keep us steadfast in Your Word. Give us Your Holy Spirit to keep us in the Truth and to confess it in purity. Lord have mercy. Amen.” Rev. Dr. Matthew Harrison, President of the Lutheran Church-Missouri Synod, joins Rev. Brady Finnern to discuss why a Quia subscription is still important for the 21st century Church. Find your copy of the Book of Concord - Concordia Reader's Edition at cph.org or read online at bookofconcord.org. Study the Lutheran Confession of Faith found in the Book of Concord with lively discussions led by host Rev. Brady Finnern, President of the LCMS Minnesota North District, and guest LCMS pastors. Join us as these Christ-confessing Concordians read through and discuss our Lutheran doctrine in the Book of Concord in order to gain a deeper understanding of our Lutheran faith and practical application for our vocations. Submit comments or questions to: listener@kfuo.org.
•Hefziba Livingstone Originally from Venezuela currently residing in the United States where she not calls home. She has always had a passion for all forms of arts and music was a big part of my life growing up. She always loved singing and dancing , she has memories which she will treasure of her grandfather and the sound of his trumpet. •She recalls recording herself by singing into her Sony waterproof radio with a passion of becoming a fashion designer. A passion she couldn't leave behind since she designs her own outfits, and currently developing her own brand. Continuing with her love of music, in her mid 20's she joined a rock band for a few months however in her mid 30's she started singing in her local church choir. •In 2020, she formally started writing and producing her own music sharing the transformative love of Jesus Christ who is her joy and passion. The Gospel of grace and peace is a light to the world and she is honored to be part of proclaiming Jesus! •Hefziba enjoys producing music that inspires faith and hope. She believes that we all have a gift to offer and believes in partnering with God to become all that we were created to be for His Glory. She others, “Our life can be impactful to the life of others, and I know that love never fails.” She believes making music is her joy and she will continue to release the sounds of Heaven on earth. •Her single “Gracefully Yours” (featuring Matthew Harrison) & most recently “Jesus Is The Reason” is available on all digital outlets. •Please send Let's Talk: Gospel Music Gold an email sharing your thoughts about this show segment also if you have any suggestions of future guests you would like to hear on the show. Send the email to letstalk2gmg@gmail.com •You may Subscribe to be alerted when the newest episode is published. Subscribe on Spotify and we will know you are a regular listener. All 4 Seasons of guests are still live; check out some other Podcast Episodes •LET'S TALK: GOSPEL MUSIC GOLD RADIO SHOW AIRS EVERY SATURDAY 9:00 AM CST / 10:00 AM EST ON WMRM-DB INTERNET RADIO STATION AND WJRG RADIO INTERNET STATION 12:00 PM EST / 11:00 AM CST •Both the Podcast and Radio shows are heard anywhere in the World on the Internet! •BOOK RELEASE! •Legacy of James C. Chambers And his Contributions to Gospel Music History •Available for purchase on Amazon.com
The Rev. Dr. Matthew C. Harrison is president of The Lutheran Church—Missouri Synod. His published works include At Home in the House of My Fathers, A Little Book on Joy, and an English translation of Johann Gerhard's Meditations on Divine Mercy — recently featured as the Lutheran Ladies' Book Club's 2024 Reformation read. In this episode, Pastor Harrison tells the stories behind this little book — both Gerhard's story as author and his own as translator. Who is Johann Gerhard, and why is he one of the great Lutheran theologians? Which of Gerhard's meditations does Harrison keep revisiting in his own prayer life, and why? At the end of the episode, Erin takes the opportunity to ask Pastor Harrison some more personal questions: Who are the most important women in his life? What are the coolest things he's gotten to do as president of the LCMS? Who is the person who keeps him most humble? Get to know both Gerhard's Meditations and President Harrison more deeply in this warm and personal interview. Click to listen to our recent book club wrap-up episode or order your own copy of Gerhard's Meditations on Divine Mercy. Connect with the Lutheran Ladies on social media in The Lutheran Ladies' Lounge Facebook discussion group (facebook.com/groups/LutheranLadiesLounge) and on Instagram @lutheranladieslounge. Follow Sarah (@hymnnerd), Rachel (@rachbomberger), and Erin (@erinaltered) on Instagram! Sign up for the Lutheran Ladies' Lounge monthly e-newsletter here, and email the Ladies at lutheranladies@kfuo.org.
Pr. Matthew Harrison, President of the Lutheran Church-Missouri Synod Take Courage: Encouraging Words for Discouraging Times The post 2814. The Lutheran Church of Australia's Approval of Women's Ordination – Pr. Matt Harrison, 10/7/24 first appeared on Issues, Etc..
What does it take to chase your dreams?
Pr. Matthew Harrison, President of the Lutheran Church-Missouri Synod The Collection: Mercy in Action LCMS Mercy The post 2183. The Apostle Paul's Collection for the Jerusalem Church – Pr. Matt Harrison, 8/5/24 first appeared on Issues, Etc..
Niigaan Sinclair, a columnist, professor, and author, has both studied and lived the Indigenous experience in Manitoba. His book, Wînipêk: Visions of Canada from an Indigenous Centre, explores Winnipeg as the "ground zero" of Indigenous relations in Canada. From the Heart of Canada, Matthew Harrison invites Sinclair to discuss Manitoba's history, Indigenous communities, radical solutions to injustice and violence, and reconciliation.
In his latest segment of From the Heart of Canada, Matthew Harrison explores the phenomenon of "Trumpism" and the ascent of the controversial president. What attracted his audience? What drove the far-right movement? And what are the implications for Canada? Let's delve into the politics.
Maggie is joined by Matthew and Jess from the The University of Melbourne to discuss inclusive esports programs in schools.Jess and Matthew are conducing research to understand the gaps in regional and rural areas around resources and infrastructure of and how they can help remove some of those barriers for schools and families, helping students to have equity learning experiences whilst enjoying esports. They have also looked at inclusivity for females in esports, and ways to make it more accessible and better represented.
Will Goodon from the Manitoba Métis Federation joins Matthew Harrison at the U Multicultural studio to delve into the history which shaped Métis nationhood. The two explore Indigenous identity fraud and its threat to authentic Métis culture and heritage. Who are the Métis people? What does the future look like for the Métis Nation? Find out from the Heart of Canada.
How can a person make a difference in the world? Ryan Keeping, a 27-year-old from Halifax, has been running across Canada to find that answer. Starting on April 1st from St. Johns, Newfoundland, Ryan aims to cover 7,386 km in 99 days, running 75 km daily to raise funds for the Heart & Stroke Foundation of Canada. Matthew Harrison ran with Ryan to hear his story.
Why is it important to hear God's Word daily? Rev. Dr. Matthew Harrison, President of The Lutheran Church—Missouri Synod, joins Sarah during Sharathon 2024 to talk about the treasure of God's Word, what he would say to the team of founders of KFUO as they were considering this new medium of AM Radio 100 year ago, and how important our listeners and donors are as we continue this radio ministry for another 100 years. Learn more about Sharathon 2024 and give now at kfuo.org/sharathon.
we looked at President Matthew Harrison's (LCMS) article on Divine Authority and a unpublished article by Jack Cascione that was a reaction to it. https://witness.lcms.org/2023/divine-authority/
In this episode, Emily and Dave sit down with Dr. Matthew Harrison, a seasoned educator and digital innovator. Matt's journey from an accidental teacher to a champion of neurodiversity and inclusion unveils the unexpected ways gaming can foster social skills and empowerment. Matt's passion for utilizing technology to enhance social capacity building, belonging, and inclusion in education comes to the forefront. As a gamer himself, he sheds light on the transformative power of gaming in developing crucial social skills, ranging from turn-taking to effective communication. Through personal anecdotes and insights, he emphasizes how gaming can be a potent tool for leadership development, paving the way for a more inclusive society. The conversation takes a deep dive into the concept of "gaming for good." Matt discusses the innovative initiative, Next Level Collaboration—a program that employs cooperative video games to empower neurodivergent children. With co-founder and Next Level Collaboration CEO, Jess Rowlings, they not only bring lived experience to the table but also a vision for using gaming to boost confidence and social capabilities in young individuals. This venture showcases how unconventional approaches can lead to remarkable outcomes in education and leadership. Beyond gaming, the discussion expands to the significance of accessibility in leadership. Dr. Harrison provides practical insights for leaders and organizations to make workplaces more accessible and inclusive, highlighting the untapped potential of existing accessibility features within common tools and platforms. His emphasis on understanding preferred communication styles and integrating technology underscores the importance of creating environments where everyone can thrive. As the conversation wraps up, Emily and Dave reflect on the episode's key takeaways. Listeners are left with a fresh perspective on leadership—a reminder that fostering inclusion requires embracing diverse tools and strategies. Learn more about your ad choices. Visit megaphone.fm/adchoices
Pastor Baker discusses theological distinctions between Law & Gospel with guest Pastor Wes Reimnitz. Today's rumination topic is what a Lutheran is. Read the article from President Matthew Harrison at reporter.lcms.org/2023/what-is-a-lutheran. Law and Gospel is independently produced by Pastor Tom Baker. Views and opinions expressed on this program may not represent the official position of the management or ownership of KFUO Radio, The Lutheran Church—Missouri Synod. To contact Pastor Tom Baker, email tombaker@brick.net.
In this episode, we go through the timeline of what has transpired since the LCMS — largely at the behest of Matthew Harrison — published the so-called “Annotated Large Catechism”. The behavior of Synod has been anything but Christian, and wicked deeds should be exposed to the light of day. Satan is on the move, and far too many men in collars are far too willing to do his bidding. Subscribe to the podcast here. Show Notes “The New Large Catechism of the LC-MS stream” “The Apostasy of Missouri” Article includes ‘complaint' letter from Ben Meyer, Daniel Ross, and Erik Johnson, video of interaction with police, and video of Maanum's (first) announcement. “The Book of Concord Will Endure” Lutherans for Racial Justice [archive link] Bios for Matthew Gonzalez and Joshua Salzberg [archive link] “He Believes Hitler Went to Heaven — and Wants to Take Over the Lutheran Church” [archive link] https://twitter.com/CoreyJMahler/status/1616490061377175573?s=20 https://twitter.com/CoreyJMahler/status/1616581582612987906?s=20 See Also 1st Thread from Ryan Turnipseed [Twitter] 2nd Thread from Ryan Turnipseed [Twitter] "Talking Heads: On Headship, Teaching, and Women in the Church” “Against the Antichrist" “Statement on the death of George Floyd and the ensuing riots” [archive link] “Letter to President Harrison of the LCMS” Contrast Harrison's Response to the Terrorist Attack in Waukesha [This is not actually a link because he said nothing about it.] “Waukesha: One Year Later” Further Reading "‘In All Things': 20,000 attend LCMS Youth Gathering” LCMS National Youth Gathering Kennedy v. Louisiana [Wikipedia] Warning: This fact pattern is deeply unpleasant. Lawrence v. Texas [Wikipedia] “Test of Pastoral Orthodoxy” This article is another reason some LCMS pastors are less than fond of me (Mahler). “Of Fools and Demons” A bit more about our adversaries. Parental Warnings This episode will probably not interest children, and some sensitive topics (including pedophilia and rape) are briefly discussed throughout. Errata At one point, I (Mahler) state that I handed the AALC a hard drive with information pertaining to Jordan Cooper, but I misspoke, because what I handed them was, in fact, a flash drive.
Rev. Dr. Matthew Harrison, President of The Lutheran Church—Missouri Synod, joins Andy and Sarah during Sharathon 2023 to talk about how KFUO Radio is a valuable part of the mission and work of The Lutheran Church—Missouri Synod, the importance of hearing and studying God's Word regularly, and the importance of the listener support for this broadcast ministry. It's Sharathon 2023, and we need YOUR support! By God's grace and with your generous support, we've been sharing the Gospel for close to 99 years to millions of listeners worldwide. Our Bible studies help to explain and deepen your understanding of God's Word. Our worship services proclaim salvation in Christ and give you the words that the church has always used to proclaim the Gospel. And our hymns—the sacred music of the church—are the joyous exultation of God's people that explain, proclaim, and announce the joy of salvation in Christ alone. In short, your gift makes it possible for the listener-supported Broadcast Ministry of KFUO Radio to continue filling our world with God's Word. Start, sustain, or strengthen your partnership with KFUO Radio during Sharathon 2023. Give now at kfuo.org/sharathon.
Original Release on February 6th, 2023: As new gene therapies are researched, developed and begin clinical trials, what hurdles must genetic medicine overcome before these therapies are commonly available? Head of U.S. Pharmaceuticals Terence Flynn and Head of U.S. Biotech Matthew Harrison discuss. ----- Transcript -----Terence Flynn: Welcome to Thoughts on the Market. I'm Terence Flynn, Head of U.S. Pharma for Morgan Stanley Research. Matthew Harrison: And I'm Matthew Harrison, Head of U.S. Biotech. Terence Flynn: And on this special episode of Thoughts on the Market, we'll be discussing the bold promise of genetic medicine. It's Monday, February 6th, at 10 a.m. in New York. Terence Flynn: 2023 marks 20 years since the completion of the Human Genome Project. The unprecedented global scientific collaboration that generated the first sequence of the human genome. The pace of research in molecular biology and human genetics has not relented since 2003, and today we're at the start of a real revolution in the practice of medicine. Matthew what exactly is genetic medicine and what's the difference between gene therapy and gene editing? Matthew Harrison: As I think about this, I think it's important to talk about context. And so as we've thought about medical developments and drug development over the last many decades, you started with pills. And then we moved into drugs from living cells. These are more complicated drugs. And now we're moving on to editing actual pieces of our genome to deliver potentially long lasting cures. And so this opens up a huge range of new treatments and new opportunities. And so in general, as we think about it, they're basically two approaches to genetic medicine. The first is called gene therapy, and the second is called gene editing. The major difference here is that in gene therapy you just deliver a snippet of a gene or pre-programmed message to the body that then allows the body to make the protein that's missing, With gene editing, instead what you do is you go in and you directly edit the genes in the person's body, potentially giving a long lasting cure to that person. So obviously two different approaches, but both could be very effective. And so, Terence, as you think about what's happening in research and development right now, you know, how long do you think it's going to be before some of these new therapies make it to market? Terence Flynn: As we think about some of the other technologies you mentioned, Matthew, those took, you know, decades in some cases to really refine them and broaden their applicability to a number of diseases. So we think the same is likely to play out here with genetic medicine, where you're likely to see an iterative approach over time as companies work to optimize different features of these technologies. So as we think about where it's focused right now, it's being primarily on the rare genetic disease side. So diseases such as hemophilia, spinal muscular atrophy and Duchenne muscular dystrophy, which affect a very small percentage of the population, but the risk benefit is very favorable for these new medicines. Now, there are currently five gene therapies approved in the U.S. and several more on the horizon in later stage development. No gene editing therapies have been approved yet, but there is one for sickle cell disease that could actually be approved next year, which would be a pretty big milestone. And the majority of the other gene editing therapies are actually in earlier stages of development. So it's likely going to be several years before those reach the market. As, again as we've seen happen time and time again in biopharma as these new therapies and new platforms are rolled out they have very broad potential. And obviously there's a lot of excitement here around these genetic medicines and thinking about where these could be applied. But I think before we go there, Matthew, obviously there are still some hurdles that needs to be addressed before we see a broader rollout here. So maybe you could touch on that for us. Matthew Harrison: You're right, there are some issues that we're still working through as we think about applying these technologies. The first one is really delivery. You obviously can't just inject some genes into the body and they'll know what to do. So you have to package them somehow. And there are a variety of techniques that are in development, whether using particles of fat to shield them or using inert viruses to send them into the body. But right now, we can't deliver to every tissue in every organ, and so that limits where you can send these medicines and how they can be effective. So there's still a lot of work to be done on delivery. And the second is when you go in and you edit a gene, even if you're very precise about where you want to edit, you might cause some what we call off target effects on the edges of where you've edited. And so there's concern about could those off target effects lead to safety issues. And then the third thing which we've touched on previously is durability. There's potentially a difference between gene therapy and gene editing, where gene editing may lead to a very long lasting cure, where different kinds of gene therapies may have longer term potential, but some may need to be redosed. Terence, as we turn back to thinking about the progress of the pipeline here, you know, what are the key catalysts you're watching over 23 and 24? Terence Flynn: You know, as everyone probably knows, biopharma is a highly regulated industry. We have the FDA, the Food and Drug Administration here in the U.S., and we have the EMA in Europe. Those are the bodies that, you know, evaluate risk benefit of every therapy that's entering clinical trials and ultimately will reach the market. So this year we're expecting much of the focus for the gene editing companies to be broadly on regulatory progress. So again, this includes completion of regulatory filings here in the U.S. and Europe for the sickle cell disease drug that I mentioned before. And then something that's known as an IND filing. So essentially what companies are required to do is file that before they conduct clinical trials in humans in the U.S. There are companies that are pursuing this for hereditary angioedema and TTR amyloidosis. Those, if successful, would allow clinical trials to be conducted here in the U.S. and include U.S. patients. The other big thing we're watching is additional clinical data related to durability of efficacy. So, I think we've seen already with some of the gene therapies for hemophilia that we have durable efficacy out to five years, which is very exciting and promising. But the question is, will that last even longer? And how to think about gene therapy relative to gene editing on the durability side. And then lastly, I'd say safety. Obviously that's important for any therapy, but given some of the hurdles still that you mentioned, Matthew, that's obviously an important focus here as we look out over the longer term and something that the companies and the regulators are going to be following pretty closely. So again, as we think about the development of the field, one of the other key questions is access to patients. And so pricing reimbursement plays a key role here for any new therapy. There are some differences here, obviously, because we're talking about cures versus traditional chronic therapies. So maybe Matthew you could elaborate on that topic. Matthew Harrison: So as you think about these genetic medicines, the ones that we've seen approved have pretty broad price ranges, anywhere from a million to a few million dollars per patient, but you're talking about a potential cure here. And as I think about many of the chronic therapies, especially the more sophisticated ones that patients take, they can cost anywhere between tens of thousands and hundreds of thousands of dollars a year. So you can see over a decade or more of use how they can actually eclipse what seems like a very high upfront price of these genetic medicines. Now, one of the issues obviously, is that the way the payers are set up is different in different parts of the world. So in Europe, for example, there are single payer systems for the patient never switches between health insurance carriers. And so therefore you can capture that value very easily. In the U.S., obviously it's a much more complicated system, many people move between payers as they switch jobs, as you change from, you know, commercial payers when you're younger to a government payer as you move into Medicare. And so there needs to be a mechanism worked out on how to spread that value out. And so I think that's one of the things that will need to evolve. But, you know, it's a very exciting time here in genetic medicine. There's significant opportunity and I think we're on the cusp of really seeing a robust expansion of this field and leading to many potential therapies in the years to come. Terence Flynn: That's great, Matthew. Thanks so much for taking the time to talk today. Matthew Harrison: Great speaking with you, Terrence. Terence Flynn: As a reminder, if you enjoy Thoughts on the Market, please take a moment to rate and review us on Apple Podcasts app. It helps more people to find the show.
We all know individuals who are good at a skill without even trying. They can write, play a sport, or play an instrument with seemingly no effort. Is it possible that some people are just more talented than others? If so, does that apply to acting as well? Today, acting Coach Matthew Harrison and I delve deep into the concept of talent; where the idea came from and why society is obsessed by it. We discuss why Mozart had no talent and how some actors can give incredible performances without any prior training. Our conversation references some of the celebrated neuroscientists and psychologist listed below: Anders Ericsson - PEAK: Secrets from the New Science of Expertise David Eagleman - LIVEWIRED -The inside story of the ever changing brain David Eagleman - THE RUNAWAY SPECIES- How human creativity remakes the world Brene Brown - DARING GREATLY Other books of interest: Yuval Noah Harari - HOMO SAPIENS Gabor Maté - IN THE REALM OF HUNGRY GHOSTS Gabor Maté - WHEN THE BODY SAYS NO Daniel Kanneman - THINKING FAST AND SLOW Brene Brown - THE POWER OF VULNERABILITY Oprah Winfrey - WHAT HAPPENED TO YOU?: Conversations on Trauma, Resilience, and Healing
Matthew Harrison is head of the largest (supposedly) Confessional Lutheran body in the Western world — the LCMS. During his tenure, he has overseen the greatest decline in membership in the history of the LCMS, the closure of LCMS schools and congregations, and the collapse of LCMS organizations. Now, to top off his legacy, Harrison is pushing false doctrine via 'new' versions of core confessional, Lutheran documents (e.g., the Small Catechism and the Large Catechism). He is even exporting this doctrine abroad. Of course, the focus on exporting doctrine is nothing new — Harrison has spent his tenure with his focus everywhere but on the sheep God entrusted to his care (and for which God will one day command him to account). Harrison and those around him personally hate this podcast and its hosts, because we are speaking the truth about the Christian faith and about what men like Harrison are doing to the Church. In this episode, we review Harrison's recent letter 'denouncing disturbing ideologies'. Christians do not speak as Harrison speaks. We will all have to choose a side. For their part, the following men have thrown in their lot with Satan and the kingdom of Antichrist: Matthew Harrison, President of the LCMS Peter K. Lange, 1st Vice President of the LCMS John C. Wohlrabe Jr., 2nd Vice President of the LCMS Scott R. Murray, 3rd Vice President of the LCMS Nabil S. Nour, 4th Vice President of the LCMS Christopher Esget, 5th Vice President of the LCMS Benjamin T. Ball, 6th Vice President of the LCMS the 35 District Presidents of the LCMS Subscribe to the podcast here. Show Notes "President Harrison denounces disturbing ideologies" "Statement on the death of George Floyd and the ensuing riots" The New Catechism of the LC-MS [YouTube] YouTube review of the 'Annotated' LC. See Also Coverture [Wikipedia] "The Stranger" by Rudyard Kipling "Letter to President Harrison of the LCMS" "Test of Pastoral Orthodoxy" "We Are Stronger Together" "The Apostasy of Missouri" Further Reading C. F. W. Walther on Slavery, Humanism, and the Bible Antifaschistische Aktion "On the Year-Zero Revolutionary" Parental Warnings The word "jackass" is used once in this episode at around 01:30:00.
In today's episode, your tour guides tell you a story about the Lutheran Church-Missouri Synod and a simple fascist often called "The Slavery Lutheran."Machaira Action exposéThe Apostasy of MissouriFollow us on Twitter @MammonburgpodFollow the hosts on Twitter: Jackal, Finch, Josiah, and Phil.Audio CreditsBaba O'Riley - The WhoDreams - DJ QuadsHungry - LiadiiiSentimental – Dan Darmawan Noah - Calin Moraru BeatsPastor Ben Squires on Recent Events in LCMSMaanum, AnnouncementCorey Mahler arguing with cops lolSimpsons: Lisa creates LutheransDisco Elysium: EggheadTrump about CharlottesvilleJason Kessler after CharlottesvilleJordan B Cooper on Christian NationalismNBC: Christian Nationalism On The RiseVacation Sex
Host: Kevin Smith Dives into the weekly news most impactful to the HeartlandHEADLINESA Mighty Controversy Is This Lutheran Catechism - Christianity Today - https://www.christianitytoday.com/news/2023/february/lutheran-catechism-concordia-publishing-critics-matthew-har.html?fbclid=IwAR1fTmGTD5bmljUm-3HBHoRFC5hLjOje6grzS6mBva7gNUEWM8nxhYvfRew_aem_Abw0xp27VoagVA-hQ7b1jmV9_JapK22txw534SD7aQXJ5G56w_NVpU5qBLinbl0HeGWP843SZL01HxQ3AwkN4A10p-nKzngDDxaiJHUkHX8dKbbAeztj2L-ofhC-x1Xbe4DkeYmYvQD04fuyzi_UwtrQLutherans for Racial Justice - https://lutheransforracialjustice.com/glass-onion?fbclid=IwAR1Qb-1XAlAgwMdvvvuhp33CjmmO1MVlioPa0fxhXczOFH1NlEPjPISwqZELIGHTNING ROUNDMontanaBill in the state Legislature seeks to regulate science curriculum in public schools.Montana Public Radio - https://www.mtpr.org/montana-news/2023-02-07/bill-would-ban-the-teaching-of-scientific-theories-in-montana-schools?utm_medium=social&utm_source=facebook.com&utm_term=nprnews&utm_campaign=npr&fbclid=IwAR392qd4WeNdpxNhtV73I8wVEXKXOOubKD9qdqzMGInE6P0KVobnrUkkZWw&mibextid=Zxz2cZArizonaFraud rampant in school-voucher program!AZ Central - https://www.azcentral.com/story/news/politics/arizona/2018/10/29/misspent-school-voucher-funds-exceed-700-k-little-recovered/1780495002/?fbclid=IwAR3Hu6hobnEXTu2ayvOSaGA7Xdf8um1VVirHq_OO8vnW0RMtbt22EKAErwk&mibextid=Zxz2cZ#ldw15g70l8d7ldvqauhSuper Bowl LVII betting.Wall Street Journal - https://www.wsj.com/articles/super-bowl-betting-projected-to-hit-record-16-billion-11675731607KansasOld homeowners get grantsShawnee Mission Post - https://shawneemissionpost.com/2023/02/07/lenexa-home-improvement-grants-193186/New homeowners get helpYahoo Finance - https://finance.yahoo.com/news/kansas-first-time-homebuyer-assistance-161649713.htmlMissouriOSHA fines against a Lone Jack, Missouri, cattle processor. KSHB Kansas - https://www.kshb.com/news/local-news/lone-jack-cattle-processor-again-facing-osha-fines-over-workplace-safety-concerns#MOLeg Republicans an emphatic YES! for kids parading with guns.The Guardian - https://www.theguardian.com/us-news/2023/feb/09/missouri-rejects-ban-children-carrying-guns-in-publicThe first weekend numbers are in after legalized marijuana hit the state of Missouri.Leafly - https://www.leafly.com/news/politics/missouri-tops-12-million-in-marijuana-sales-during-opening-rec-weekendOklahomaTranquil Trans Protest.Fox News - https://okcfox.com/news/local/protests-at-state-capitol-sparking-nationwide-outrage-gov-governor-kevin-stitt-ok-oklahoma-state-of-the-state-transgender-trans-gender-rights-pro-law-legislature-legislative-gender-affirming-care-trust-women-freedom-oklahomaIowaThe U.S. Department of Labor vs Construction Bad Actors.Iowa Capital Dispatch - https://iowacapitaldispatch.com/2023/02/03/feds-file-lawsuits-accusing-two-iowa-companies-of-labor-violations/Medical malpractitioners protected by state republicansDes Moines Register - https://www.desmoinesregister.com/story/news/politics/2023/02/08/iowa-house-votes-to-limit-medical-malpractice-damages-a-gop-priority/69866480007/Lastly, The Trifurcation of the GOPIndy 100 - https://www.indy100.com/politics/donald-trump-ron-desantis-republican-party?utm_campaign=Main&utm_content=Echobox&utm_medium=Social&utm_source=Twitter&utm_term=Autofeed#Echobox=1675808611The Guardian - https://www.theguardian.com/us-news/2023/feb/09/nikki-haley-presidential-run-ron-desantis-donald-trump-poll?CMP=Share_iOSApp_Other
Host: Kevin Smith Dives into the weekly news most impactful to the HeartlandHEADLINESA Mighty Controversy Is This Lutheran Catechism - Christianity Today - https://www.christianitytoday.com/news/2023/february/lutheran-catechism-concordia-publishing-critics-matthew-har.html?fbclid=IwAR1fTmGTD5bmljUm-3HBHoRFC5hLjOje6grzS6mBva7gNUEWM8nxhYvfRew_aem_Abw0xp27VoagVA-hQ7b1jmV9_JapK22txw534SD7aQXJ5G56w_NVpU5qBLinbl0HeGWP843SZL01HxQ3AwkN4A10p-nKzngDDxaiJHUkHX8dKbbAeztj2L-ofhC-x1Xbe4DkeYmYvQD04fuyzi_UwtrQLutherans for Racial Justice - https://lutheransforracialjustice.com/glass-onion?fbclid=IwAR1Qb-1XAlAgwMdvvvuhp33CjmmO1MVlioPa0fxhXczOFH1NlEPjPISwqZELIGHTNING ROUNDMontanaBill in the state Legislature seeks to regulate science curriculum in public schools.Montana Public Radio - https://www.mtpr.org/montana-news/2023-02-07/bill-would-ban-the-teaching-of-scientific-theories-in-montana-schools?utm_medium=social&utm_source=facebook.com&utm_term=nprnews&utm_campaign=npr&fbclid=IwAR392qd4WeNdpxNhtV73I8wVEXKXOOubKD9qdqzMGInE6P0KVobnrUkkZWw&mibextid=Zxz2cZArizonaFraud rampant in school-voucher program!AZ Central - https://www.azcentral.com/story/news/politics/arizona/2018/10/29/misspent-school-voucher-funds-exceed-700-k-little-recovered/1780495002/?fbclid=IwAR3Hu6hobnEXTu2ayvOSaGA7Xdf8um1VVirHq_OO8vnW0RMtbt22EKAErwk&mibextid=Zxz2cZ#ldw15g70l8d7ldvqauhSuper Bowl LVII betting.Wall Street Journal - https://www.wsj.com/articles/super-bowl-betting-projected-to-hit-record-16-billion-11675731607KansasOld homeowners get grantsShawnee Mission Post - https://shawneemissionpost.com/2023/02/07/lenexa-home-improvement-grants-193186/New homeowners get helpYahoo Finance - https://finance.yahoo.com/news/kansas-first-time-homebuyer-assistance-161649713.htmlMissouriOSHA fines against a Lone Jack, Missouri, cattle processor. KSHB Kansas - https://www.kshb.com/news/local-news/lone-jack-cattle-processor-again-facing-osha-fines-over-workplace-safety-concerns#MOLeg Republicans an emphatic YES! for kids parading with guns.The Guardian - https://www.theguardian.com/us-news/2023/feb/09/missouri-rejects-ban-children-carrying-guns-in-publicThe first weekend numbers are in after legalized marijuana hit the state of Missouri.Leafly - https://www.leafly.com/news/politics/missouri-tops-12-million-in-marijuana-sales-during-opening-rec-weekendOklahomaTranquil Trans Protest.Fox News - https://okcfox.com/news/local/protests-at-state-capitol-sparking-nationwide-outrage-gov-governor-kevin-stitt-ok-oklahoma-state-of-the-state-transgender-trans-gender-rights-pro-law-legislature-legislative-gender-affirming-care-trust-women-freedom-oklahomaIowaThe U.S. Department of Labor vs Construction Bad Actors.Iowa Capital Dispatch - https://iowacapitaldispatch.com/2023/02/03/feds-file-lawsuits-accusing-two-iowa-companies-of-labor-violations/Medical malpractitioners protected by state republicansDes Moines Register - https://www.desmoinesregister.com/story/news/politics/2023/02/08/iowa-house-votes-to-limit-medical-malpractice-damages-a-gop-priority/69866480007/Lastly, The Trifurcation of the GOPIndy 100 - https://www.indy100.com/politics/donald-trump-ron-desantis-republican-party?utm_campaign=Main&utm_content=Echobox&utm_medium=Social&utm_source=Twitter&utm_term=Autofeed#Echobox=1675808611The Guardian - https://www.theguardian.com/us-news/2023/feb/09/nikki-haley-presidential-run-ron-desantis-donald-trump-poll?CMP=Share_iOSApp_Other
As new gene therapies are researched, developed and begin clinical trials, what hurdles must genetic medicine overcome before these therapies are commonly available? Head of U.S. Pharmaceuticals Terence Flynn and Head of U.S. Biotech Matthew Harrison discuss. ----- Transcript -----Terence Flynn: Welcome to Thoughts on the Market. I'm Terence Flynn, Head of U.S. Pharma for Morgan Stanley Research. Matthew Harrison: And I'm Matthew Harrison, Head of U.S. Biotech. Terence Flynn: And on this special episode of Thoughts on the Market, we'll be discussing the bold promise of genetic medicine. It's Monday, February 6th, at 10 a.m. in New York. Terence Flynn: 2023 marks 20 years since the completion of the Human Genome Project. The unprecedented global scientific collaboration that generated the first sequence of the human genome. The pace of research in molecular biology and human genetics has not relented since 2003, and today we're at the start of a real revolution in the practice of medicine. Matthew what exactly is genetic medicine and what's the difference between gene therapy and gene editing? Matthew Harrison: As I think about this, I think it's important to talk about context. And so as we've thought about medical developments and drug development over the last many decades, you started with pills. And then we moved into drugs from living cells. These are more complicated drugs. And now we're moving on to editing actual pieces of our genome to deliver potentially long lasting cures. And so this opens up a huge range of new treatments and new opportunities. And so in general, as we think about it, they're basically two approaches to genetic medicine. The first is called gene therapy, and the second is called gene editing. The major difference here is that in gene therapy you just deliver a snippet of a gene or pre-programmed message to the body that then allows the body to make the protein that's missing, With gene editing, instead what you do is you go in and you directly edit the genes in the person's body, potentially giving a long lasting cure to that person. So obviously two different approaches, but both could be very effective. And so, Terence, as you think about what's happening in research and development right now, you know, how long do you think it's going to be before some of these new therapies make it to market? Terence Flynn: As we think about some of the other technologies you mentioned, Matthew, those took, you know, decades in some cases to really refine them and broaden their applicability to a number of diseases. So we think the same is likely to play out here with genetic medicine, where you're likely to see an iterative approach over time as companies work to optimize different features of these technologies. So as we think about where it's focused right now, it's being primarily on the rare genetic disease side. So diseases such as hemophilia, spinal muscular atrophy and Duchenne muscular dystrophy, which affect a very small percentage of the population, but the risk benefit is very favorable for these new medicines. Now, there are currently five gene therapies approved in the U.S. and several more on the horizon in later stage development. No gene editing therapies have been approved yet, but there is one for sickle cell disease that could actually be approved next year, which would be a pretty big milestone. And the majority of the other gene editing therapies are actually in earlier stages of development. So it's likely going to be several years before those reach the market. As, again as we've seen happen time and time again in biopharma as these new therapies and new platforms are rolled out they have very broad potential. And obviously there's a lot of excitement here around these genetic medicines and thinking about where these could be applied. But I think before we go there, Matthew, obviously there are still some hurdles that needs to be addressed before we see a broader rollout here. So maybe you could touch on that for us. Matthew Harrison: You're right, there are some issues that we're still working through as we think about applying these technologies. The first one is really delivery. You obviously can't just inject some genes into the body and they'll know what to do. So you have to package them somehow. And there are a variety of techniques that are in development, whether using particles of fat to shield them or using inert viruses to send them into the body. But right now, we can't deliver to every tissue in every organ, and so that limits where you can send these medicines and how they can be effective. So there's still a lot of work to be done on delivery. And the second is when you go in and you edit a gene, even if you're very precise about where you want to edit, you might cause some what we call off target effects on the edges of where you've edited. And so there's concern about could those off target effects lead to safety issues. And then the third thing which we've touched on previously is durability. There's potentially a difference between gene therapy and gene editing, where gene editing may lead to a very long lasting cure, where different kinds of gene therapies may have longer term potential, but some may need to be redosed. Terence, as we turn back to thinking about the progress of the pipeline here, you know, what are the key catalysts you're watching over 23 and 24? Terence Flynn: You know, as everyone probably knows, biopharma is a highly regulated industry. We have the FDA, the Food and Drug Administration here in the U.S., and we have the EMA in Europe. Those are the bodies that, you know, evaluate risk benefit of every therapy that's entering clinical trials and ultimately will reach the market. So this year we're expecting much of the focus for the gene editing companies to be broadly on regulatory progress. So again, this includes completion of regulatory filings here in the U.S. and Europe for the sickle cell disease drug that I mentioned before. And then something that's known as an IND filing. So essentially what companies are required to do is file that before they conduct clinical trials in humans in the U.S. There are companies that are pursuing this for hereditary angioedema and TTR amyloidosis. Those, if successful, would allow clinical trials to be conducted here in the U.S. and include U.S. patients. The other big thing we're watching is additional clinical data related to durability of efficacy. So, I think we've seen already with some of the gene therapies for hemophilia that we have durable efficacy out to five years, which is very exciting and promising. But the question is, will that last even longer? And how to think about gene therapy relative to gene editing on the durability side. And then lastly, I'd say safety. Obviously that's important for any therapy, but given some of the hurdles still that you mentioned, Matthew, that's obviously an important focus here as we look out over the longer term and something that the companies and the regulators are going to be following pretty closely. So again, as we think about the development of the field, one of the other key questions is access to patients. And so pricing reimbursement plays a key role here for any new therapy. There are some differences here, obviously, because we're talking about cures versus traditional chronic therapies. So maybe Matthew you could elaborate on that topic. Matthew Harrison: So as you think about these genetic medicines, the ones that we've seen approved have pretty broad price ranges, anywhere from a million to a few million dollars per patient, but you're talking about a potential cure here. And as I think about many of the chronic therapies, especially the more sophisticated ones that patients take, they can cost anywhere between tens of thousands and hundreds of thousands of dollars a year. So you can see over a decade or more of use how they can actually eclipse what seems like a very high upfront price of these genetic medicines. Now, one of the issues obviously, is that the way the payers are set up is different in different parts of the world. So in Europe, for example, there are single payer systems for the patient never switches between health insurance carriers. And so therefore you can capture that value very easily. In the U.S., obviously it's a much more complicated system, many people move between payers as they switch jobs, as you change from, you know, commercial payers when you're younger to a government payer as you move into Medicare. And so there needs to be a mechanism worked out on how to spread that value out. And so I think that's one of the things that will need to evolve. But, you know, it's a very exciting time here in genetic medicine. There's significant opportunity and I think we're on the cusp of really seeing a robust expansion of this field and leading to many potential therapies in the years to come. Terence Flynn: That's great, Matthew. Thanks so much for taking the time to talk today. Matthew Harrison: Great speaking with you, Terrence. Terence Flynn: As a reminder, if you enjoy Thoughts on the Market, please take a moment to rate and review us on Apple Podcasts app. It helps more people to find the show.
Pr. Matthew Harrison, President of the Lutheran Church-Missouri Synod Why Am I Joyfully Lutheran?
Adam Cox is joined by Matthew Harrison, First Contact Physiotherapy Clinical Project Manager, to discuss what MSK conditions are and how the current climate can impact MSK health. He explains how people can stay active during the winter, and what the Chartered Society of Physiotherapy is. https://www.csp.org.uk/
Pr. Matthew Harrison, President of the Lutheran Church-Missouri Synod Why Am I Joyfully Lutheran?
Pr. Matthew Harrison, President of the Lutheran Church-Missouri Synod Why Am I Joyfully Lutheran?
Author Paul Matthew Harrison, best known for his 2 volume portraiture of the friendship between he and mewithoutyou front-man, Aaron Weiss, joins to chat.
Audio recordingSermon manuscript:Our goal as Christians is to inherit heaven. Since this is our goal, we should be heavenly minded people. We should not seek to please ourselves or our fellow human beings. If we or others are pleased, then that is all well and good, but it is not what we are to be after. We seek to be pleasing to God. What is pleasing to him is his commandments. God's commandments are good, and they are always for the good. However, it does not always seem that God's commandments are for the good. Take, for example, “Honor your father and your mother.” We don't always agree with our parents and other authorities. Honoring father and mother often means that we can't do what we want to do. Or, on the other hand, we have to do what we don't want to do. That's no fun. So even though God's commandments are for our good, they often don't seem that way to us. That disconnect is maybe the primary reason why we don't do what God's commands us to do. Since our flesh often doesn't see the value of God's commandments, and since every human being has this sinful flesh, it isn't surprising that the same kind of thing that happens with us as individuals also ends up happening with groups of people, such as with states or with nations. Let's consider our own nation. God commands us not to steal. Folks know this because he has written this truth on everyone's heart. But there is no end to the swindling, corruption, fraud, and so on that happens on a daily basis. This has gotten quite sophisticated, in fact. The worst criminals among us are not the petty thieves or embezzlers that make it into the papers. They end up getting 10 year prison sentences. The worst thieves are the ones that never get prosecuted. The real big shots, throwing around billions, take whatever they can get while accomplishing nothing productive or helpful to others. They are basically a bunch of gamblers. When they win with their rigged bets in stocks and trades they are happy to take the profits. When they lose they get the government to bail them out. These thieves do not go to jail. They are highly exalted. They are hailed as great philanthropists. After their life of crime, screwing over whomever they possibly could, they hand out a small portion of their ill-gotten gains as charity. They get buildings named after them. To summon a nation to take up such fraud and corruption is a huge ask. Only the most youthful and vigorous of nations—nations that still have a sense for right and wrong—will dare to do it. Fighting wealthy and powerful people who can bribe and appoint and finagle, with the best lawyers helping them all along the way—that is dangerous and thankless. It is much easier to let things slide. So that's what we've done. That is what we will continue to do. We'll let things continue to decompose. That's how it is with so many other matters of right and wrong too. When it comes to marriage and family our nation has almost completely checked out of its responsibility to regulate that area of life. Judges used to be involved in keeping marriages together. There used to be no such thing as a no-fault divorce. People were not allowed to publicly present themselves as sexual partners with whomever they wanted. But, you know what? That's a lot of work! Getting involved in such matters is messy. It's dangerous and thankless. For several generations now parents, as God-given authorities, have also not wanted to touch the issue of their children fornicating or living together with someone to whom they are not married. God's commandment, “You shall not commit adultery,” is for our good, but it often does not seem that way. It often seems much more sensible to say, “Live, and let live.” There's no question that “Live, and let live,” is vastly easier. This laziness and apathy are also what is most important when it comes to the fifth commandment: “You shall not murder.” It seems much easier to terminate the life of an unwanted, unborn child than to be saddled with the burden of raising such a child. Unborn children who suffer from diseases are especially prone to being unwanted, and therefore murdered. A horrifying statistic that I learned when Edith was still in the womb is that 90% or more of the children who are identified as possibly to having Downs Syndrome are aborted. Caring for a child who has that condition is certainly daunting, but that is no excuse for strangling them or poisoning them. The same thing is true also at the other end of life. Several states in our nation already have laws legalizing physician-assisted suicide. Physician assisted suicide is when physicians prescribe poison to people who no longer want to live. When a disease is terminal it can seem easiest for everyone involved to just “get it over with” when it comes to a person dying. Why should family or friends waste their time keeping vigil at the death bed when they could be making money? The commandment stands: “You shall not murder.” But it doesn't seem like it is for our good. Ending lives quickly, easily, painlessly, and privately seems to be better for everyone involved. This nation has grown old and tired. The nation, of course, hasn't grown tired of making money, but that is how it is with people, too, in their old age. Greed is a vice that afflicts the elderly. We as a nation are zealous for money, but care very little about what is right and wrong. This makes us very utilitarian about moral issues. If it doesn't appear as though some activity is harmful to others, then, by all means, indulge. Anybody who would dare to make judgments about such things is unhelpful, because we all know that what is really important is the economy. So long as we continue to be the richest, most powerful, first-in-the-world nation, then we must have our priorities straight. This, however, is a very earth-bound judgment, purposely neglecting the one who is in heaven. God does not care if a person lives in America or if a person lives in Haiti. Neither being an American nor a Haitian matters. What matters is being a new creation, created by the Holy Spirit. Greatness is not defined by the amount of money or influence a person has. Greatness is a matter of keeping God's commandments. We should love the Lord our God with all our heart, soul, strength, and mind, and our neighbor as ourselves. To make America great again we do not need this politician or that politician, but a deep change of heart. We need to learn, perhaps for the first time, what true greatness is. True greatness is not democracy or earthly peace. True greatness is following after our Lord Jesus Christ. We are to deny ourselves, study God's commandments and keep them, and bear the cross that will inevitably come as a result of keeping God's commands. There's no way of accomplishing this with some political movement. There's no way to compel anyone to live as a Christian. This is only dealing with individuals. We all, as individuals, must repent of our cold, lazy, apathy towards God's commandments—the cold, lazy apathy that I hope you have seen in yourself even with the few commandments that have been pointed out today. We as individuals are guilty in such matters. We must leave behind our old, selfish attitudes and seek anew the kingdom of God and his righteousness. Let's finally get to the topic I promised you I'd speak about today: Since we have such deeply entrenched spiritual problems in our country, I can't get overly excited about the overturning of Roe vs. Wade. Overturning Roe vs. Wade was a very good thing. Roe vs. Wade was wrong. There is no such thing as a constitutional right to end another person's life. Now states are allowed to decide for themselves whether abortion is legal and under what circumstances. That might save some babies' lives. That's good. But this ruling hasn't done much to change the overall downhill direction our country has been going, spiritually speaking. I've included in your bulletin a letter from our Synod's president, Matthew Harrison. It seems to me that he struck the right tone that we should have as Christians regarding this ruling. He says we should rejoice that something which has done so much to bolster the unjust killing of innocent people has been torn down. He says we should also not be intimidated by those who gnash their teeth and will be working hard to make the murdering of the unwanted easier. Some people will never be convinced that God alone has the right to determine who lives and who dies, and that we should not take that into our own hands. Finally, president Harrison's letter tells us that we should repent. In a way, very little has changed with the overturning of Roe vs. Wade. Our lovelessness and spiritual bankruptcy has not been altered. Our failure to care for troubled and helpless women is just as egregious as it ever was. He ended his letter with: “Lord, have mercy.” This is the way it is with Christianity. We must stay the course that we have been given as Christians. We fight against evil, not just by looking for evil people over there, but by seeing that same evil within ourselves. We repent, believe the Gospel of forgiveness for Jesus's sake, and, God willing, walk by the Spirit. The source of true blessing and happiness has been the same ever since the beginning of creation. That source has always been the Lord our God. He is the one from whom all blessings flow. Adam and Eve were harmed by breaking his commandments, just as anyone and everyone inevitably and always will be harmed by breaking his commandments, even if it doesn't seem so. Adam and Eve were saved through faith in the Lord's promise of a Savior, our Lord Jesus Christ. As it was then, so it is now, and so it ever shall be for each one of us individually, as well as collectively as a state or a nation. A nation, however, cannot repent. Only individuals can repent and believe. If you really want to be helpful and patriotic on this holiday weekend, you would do better to examine your life according to the Ten Commandments than to read the Declaration of Independence. The Declaration of Independence was written by mere men. The commands and promises by which we live as Christians were given to us by God. God's Word is a sure and certain path for us Christians. It is impossible for us not to be blessed if we follow God's commandments and believe his promises. God is God. He will bring it about. No such promise can be made concerning politics or even our fine American system of government. No human measures can ever get deep enough to strangle the evil at its source. God's working is quite different. He makes a new creation. You, as Christians, are new creations. You have been raised with Christ. You are the salt of the earth. See to it that you don't lose your saltiness. Continue on loving and forgiving your family and your friends. Continue with your work, not working for money or for praise, but for the good of those whom God puts into your life. As a summary we might close with these words from Paul: “Set your mind on things above, not on earthly things. For you died, and your life is now hidden with Christ in God. When Christ, who is your life, appears, then you also will appear with him in glory.”
Jeff and Stacie respond to listener emails and voice messages, largely unpacking our perspectives on the Bible, inerrancy, LGBT inclusion, and traditional social values within conservative Christianity. We also weigh in on the leaked letter from LCMS president Matthew Harrison to the board of regents at Concordia University Wisconsin. If you have known us in our old lives within the orbit of American evangelicalism and conservative Lutheranism, this may infuriate you, but we mean only to share with you honestly what we're thinking and experiencing these days. Stick through hour and ten minutes of banter to hear a discussion of whether sex-positive BDSM dungeons are safer than Christian summer camp.
Pr. Matthew Harrison, President of the Lutheran Church-Missouri Synod Why Am I Joyfully Lutheran?
The Rev. Dr. Matthew C. Harrison, President of The Lutheran Church—Missouri Synod, joins Andy and Sarah during Sharathon 2022 to talk about why it's important to hear God's Word daily, how KFUO Radio supports listeners in their vocations, and the role of joyful giving in the work of LCMS ministries such as KFUO Radio. Give now for Sharathon 2022 at kfuo.org/sharathon.
Pr. Matthew Harrison, President of the Lutheran Church-Missouri Synod Why Am I Joyfully Lutheran?
Nik Sandman interviews Matthew Harrison, President of The Lutheran Church- Missouri Synod, regarding the war between Russia and Ukraine. March 4th, 2022 --- Send in a voice message: https://anchor.fm/knna-broadcasting/message
We have all manner of leaders and powerful people who care more about their power than their relationship with God. But even if they don't repent we must. And that is the second truth: now is the time for us to repent. Joe Biden is President of the United States. Vladimir Putin is President of Russia. Greg Abbot is governor of Texas. Matthew Harrison is President of the LCMS. Michael Newman is President of the LCMS Texas District. You might have thoughts about each of these men and their need to repent. But that is for them to deal with. We each must repent and rejoice in knowing that God has prepared a level and straight path to life and salvation: the path of faith that leads us to Jesus.
With recent signals from the Federal Reserve and new data on the Omicron variant, there's a lot that could impact the shape of 2022, but for now the core of our outlook remains unchanged.----- Transcript -----Welcome to Thoughts on the Market. I'm Andrew Sheets, Chief Cross Asset Strategist for Morgan Stanley. Along with my colleagues, bring you a variety of perspectives, I'll be talking about trends across the global investment landscape and how we put those ideas together. It's Friday, December 17th, at 2 p.m. in London.Every year, the economists and strategists at Morgan Stanley come together and try to forecast what the next year could look like. And then, as always seems to be the case, something happens. The world, after all, is an unpredictable place.This year, these 'somethings' have come thick and fast. As my colleague Matthew Harrison, U.S. biotechnology analyst, and I discussed on this program last week, the Omicron variant appears to be highly contagious and likely to lead to a large wave of winter infections.At almost the same time, the US Federal Reserve, arguably the world's most important central bank, has been sounding less tolerant of inflation, leading Morgan Stanley's economists to now expect a quicker end to the central bank's bond purchases and also a larger, faster increase in Federal Reserve interest rates relative to what we thought just a month ago.Both are major developments. But while they change some of our investment strategy around the edges, we don't think, for now, they change the main story for 2022.To understand why, let's start with the Federal Reserve. Yes, the Fed is now likely to end bond purchases and raise interest rates sooner than we had previously assumed. But from an investment perspective, we always thought the central bank would signal an intent to be less supportive to start the new year, hoping to convince markets that they were taking inflation seriously. We had previously thought that this 'tough talk' might shift in the spring, when inflation data would come down, and the Fed wouldn't ultimately follow through on interest rate hikes. But now, it looks like they will.But in either scenario, the strategy for investors should be to position for a central bank that is indicating it wants to be less supportive. As such, we expect interest rates to move higher, especially around five-year maturities, the dollar to appreciate and U.S. and emerging markets stocks to underperform those in Europe and Japan, where the central banks are going to be more accommodating for longer. We think financials outperform as an equity sector, seeing them as a beneficiary of less central bank accommodation.The other development, of course, is Omicron, while the new variant appears to be highly contagious. Our economists at Morgan Stanley had always assumed some form of a 'winter wave' of COVID in their growth numbers, given the virus's seasonal characteristics. Economic data, for the moment, has actually held up quite well and global activity has been less impacted by each incremental COVID wave. And we also need to consider the entire year, not just what could be a very difficult month or two of high COVID cases. All of these together are why our base case remains for strong global growth in the next year, despite the currently worrying headlines.Both new developments, however, require close observation. The Fed looks much more willing to shift in either direction than it has before, while the full impact of Omicron may not be seen for several more weeks. For now, however, we think a backdrop of good global growth and less central bank support remains the outlook for 2022.Thanks for listening. Subscribe to Thoughts on the Market on Apple Podcasts, or wherever you listen, and leave us a review. We'd love to hear from you.
The last week brought new evidence regarding the transmissibility, immune evasion and disease severity of Omicron, and with it, more clarity on the coming weeks and months.----- Transcript -----Welcome to Thoughts on the Market. I'm Matthew Harrison, Biotechnology Analyst. Along with my colleagues, bringing you a variety of perspectives, today I'll be discussing our updated thoughts on the COVID 19 pandemic and the impact of Omicron. It's Thursday, December 16th at 10:00 a.m. in New York. Since Omicron was first discovered, we've been using the framework of transmissibility, immune evasion and disease severity to think about its impact. Over the last week, the level of evidence on all three topics has increased significantly. So first, on transmissibility. The ability of Omicron to outcompete the prior dominant variant, Delta, now appears clear. We have evidence in South Africa, the UK and Denmark, with Omicron now dominant in central London and set to be the dominant variant in the UK over the next few days. The US is a few weeks behind Europe in terms of spread, but we would expect a similar pattern. Cases are now rising globally, driven by Omicron's transmissibility. This is a combination of factors driven by one, its innate transmissibility, and second, its immune evasion properties, which have dramatically increased the percentage of the population susceptible to infection. We now have multiple studies, which generally come to a similar conclusion. Two doses of vaccination or a single prior infection provide little to no barrier against infection. Two doses of vaccination do, however, provide protection against severe outcomes like hospitalization or death. This is around a 70% relative reduction versus those who are not vaccinated based on preliminary data. Three doses of vaccination or two doses of vaccination and a prior infection provide a greater barrier against infection. Preliminary data here suggests a 75% relative reduction to those without three doses or two doses and a prior infection. Importantly, since a limited proportion of the population has been boosted - we estimate at about mid-teens percentage of the total US population - the vast majority of the population is again susceptible to an infection with Omicron. And finally, on disease severity. The data out of South Africa continue to suggest the percentage of patients with severe outcomes is lower relative to the prior Delta wave. This means that there are less people in the ICU and less people on a ventilator as a proportion of the total people infected compared with Delta. That said, it's important to remember that even with a lower proportion of people having severe disease, if Omicron drives a wave of infections that is much higher than Delta, the overall disease burden could still be very high. So this leads us to what is our outlook on infections and the ultimate impact of Omicron. The variant is likely to be dominant quickly, and we would expect to be in the steeper part of the exponential rise in cases here in the US in the next two to three weeks. We believe it is possible that the Omicron wave could have a peak in terms of total number of infections that is somewhere between 2 and 3 times higher than the prior Delta wave. However importantly, vaccination should help protect against severe outcomes. For more on Omicron, we also recently sat down for an interview with the Moderna CEO Stephane Bancel to discuss his views on that topic and more. You can see the full interview on MorganStanley.com. Thanks for listening! We hope you have a safe and enjoyable holiday season. If you enjoy Thoughts on the Market, please be sure to rate and review us on the Apple Podcast app. It helps more people find the show.
With early data in on the Omicron variant, biotechnology analyst Matthew Harrison takes us through where we stand on vaccine efficacy headed into the winter.----- Transcript -----Andrew Sheets Welcome to Thoughts on the Market. I'm Andrew Sheets, Chief Cross-Asset Strategist for Morgan Stanley Research. Matthew Harrison And I'm Matthew Harrison, Biotechnology Analyst. Andrew Sheets And on this special edition of the podcast, we'll be talking about updates on the Omicron variant and vaccine efficacy. It's Wednesday, December 8th at 4:00 p.m. in London. Matthew Harrison And it's 11:00 a.m. in New York. Andrew Sheets So, Matt, it's great to talk to you again. We've had a lot of small pieces of data come out recently on the Omicron variant and its ability or not to evade vaccines. What's the latest and what do we know? Matthew Harrison So, we've had three studies published so far. I would caution that the samples are small, and we have to take them as that, but we do have some interesting trends developing. So, the first one is: most of the data has demonstrated a substantial drop in what are called 'neutralizing titers' against two doses of the vaccine. And so that unfortunately means that protection against symptomatic infection for people that have had two doses of the vaccine is quite limited. We don't know exactly what, but it's definitely below or at 50%. What we've also learned is that a third dose can help restore some of that protection. We don't know the durability of that dose and we don't know how much protection it restores, but it does restore some protection. I think importantly, though, one of the things to remember is that most of the globe has only had two doses. And as we run through this potential spread of Omicron over the next few months, most of the globe will continue to only have two doses. So that data on two doses does suggest that there can be substantial reinfection risk for those that have had the vaccine. Andrew Sheets So Matthew, you know, when we're thinking about these numbers and we think about vaccine efficacy, maybe dropping to 50%, what does that mean in terms of the risks versus current variants and then the risks if you're not vaccinated at all? Matthew Harrison Right. So, I think there are two important things that I would say. So, the first is, what we're talking about here is symptomatic infection. Some of the other data that's come out has been on T cells. T cells are the second component of your immune system. They help kill virus once it's already infected in cells, and the T cell data looks like there remains substantial protection driven by T cells. And so, I think what that says is even though we're seeing substantial drops in protection against symptomatic infection, my hope continues to be based on these data and other data we've looked at, that protection against severe outcomes such as hospitalization and death could remain quite high. Andrew Sheets So that seems quite important for both the public health outcomes. And then, as would follow the impact in the economy, is that it might be more likely that somebody with two shots of a vaccination regime would get some form of COVID, would show symptoms, but it might be still much less likely that they would end up in the hospital with severe cases, as the vaccines would still help the body protect against those more extreme outcomes. Matthew Harrison That is my hope and based on the data that we're seeing so far, I would note, as we talked about at the beginning, that all of these studies that we're seeing come out right now are preliminary. You know, my hope is over the course of the next week or so, we're going to have a lot broader data set available to answer many of the questions we're talking about. And so, we're still going to have to, take our time with this because we don't have complete information yet. Matthew Harrison So, Andrew, one of the questions I've been thinking about here is, and you touched on it in some of the questions you were asking me, is how does the market handle a substantial increase in the number of infections, but maybe a lower proportion of those infections ending up with severe disease than we've seen in previous waves? Andrew Sheets Yeah, thanks Matthew. So look, I think this distinction between, you know, any case of COVID that shows symptoms and a case of COVID that results in somebody being hospitalized, you know, that is a pretty big distinction. And again, it's quite possible to see headlines and get quite worried about headlines that you know this variant evades vaccines and kind of to think that, "oh, then vaccines are powerless to stop it" when you know, I think as your research has rightly highlighted, if the vaccines can still provide a powerful mitigant against the most severe cases against hospitalizations, and you can still avoid some of the most severe public health outcomes that really would force much bigger restrictions. And those are the types of things that would really slow economic activity and really disrupt the economy, in addition to obviously having a really tragic impact on human life. So I think that distinction is important. Andrew Sheets We obviously, as you mentioned, it's early and we need to watch it in terms of just more cases, you know, evolving again, I think we have to see how public health officials react to that. How do consumers react to it? Does it impact consumer behavior around the holidays? And you know, we do think U.S. economic activity and European economic activity are pretty strong at the moment, so they have some cushion. But obviously it needs to be monitored. Andrew Sheets I think the other economy we need to watch is China, which is operating with a zero COVID policy. So, a quite restrictive policy trying to prevent any COVID cases. You know, if the indications are that we are dealing with now two more contagious variants: the Delta variant, and the Omicron variant, you know, there's a question of, does that complicate any sort of zero COVID strategy when you are dealing with a more contagious virus? And that's another big economic story that we have to keep our eye on. Matthew Harrison Andrew, that's great. Thanks for taking the time to chat today. Andrew Sheets Matt, always great to talk to you. Andrew Sheets As a reminder, if you enjoy Thoughts on the Market, please take a moment to rate and review us on the Apple Podcasts app. It helps more people find the show.
Markets look like they will bounce back after a down day yesterday, with Apple being the only tech bright spot in a sea of red. We discuss how investors should play this final month of 2021. Plus, natural gas prices are soaring again in the U.K. and Europe as winter is on the way. Brian takes a look in his RBI. And top-rated biotech analyst Matthew Harrison of Morgan Stanley joins to discuss Merck's latest Covid-19 treatment, vaccine efficacy, and the latest in the omicron Covid variant.
Rev. Dr. Matthew Harrison gives today's sermon based on Revelation 20:7-15. Today we pray for Rev. Charles and Cheryl Ferry who serve the Lord in Taiwan. Read their story and how to support their work at lcms.org/ferry. Find your opportunity to serve at servenow.lcms.org. >> The broadcast of chapel services is brought to you by LCMS International Mission and Ministry to Armed Forces. >> Learn more at international.lcms.org and lcms.org/armedforces.
For some entrepreneurs, running a business is in their blood. On this episode, host Elliott Noble-Holt sits down with his brother and Medicopy's Senior Project Manager Matthew Harrison to share the challenges and charms of being in business with your family. Holt and Harrison talk about their family history of hustling, their impulse to create and the brotherhood bond in business.
How do you create an equitable organisation? Around the world, companies are grappling with this question as diversity, inclusion, equal opportunity and hybrid working becomes more important. Interviewer and podcast host Victoria Bentley speaks to new Partners Federico Cassani, Amit Deshmukh, Matthew Harrison, Julie Janiski and Anna Wendt about equity at Buro Happold. They discuss the role of policies and behaviour within our company and the wider built environment industry. They also explore what practical steps we can all take to ensure everyone feels empowered, whatever their background. We all have a responsibility to diversify our industry and promote a culture of inclusivity.
Paul Matthew Harrison is an author and extremely interesting man. He talked to me about signs, synchronicities and the power of imagination. In my (humble? lol) opinion, this is an episode worth listening to, if only because the content is intriguing and something I have not ever talked about. Paul has so many interesting things to say not just here, but in his books too! Check them out here: All the Clever words (Pt 1) - https://www.amazon.com/All-Clever-Words-Pages-mewithoutYou/dp/0692737553 All the Clever words (Pt 2) - https://www.amazon.com/All-Clever-Words-Pages-Pt/dp/0578448343/ref=pd_aw_fbt_img_2/132-0199801-6706424?_encoding=UTF8&pd_rd_i=0578448343&pd_rd_r=7906b644-0293-4647-aa04-093d12462e45&pd_rd_w=sytdy&pd_rd_wg=TwTJs&pf_rd_p=76cabe35-c3aa-48b9-a92c-c6e10de9edfe&pf_rd_r=459N5QK76HT30M7XKZ92&psc=1&refRID=459N5QK76HT30M7XKZ92 God Told me to Marry you - https://www.amazon.com/God-Told-Me-Marry-You/dp/0692924450/ref=mp_s_a_1_3?dchild=1&keywords=god+told+me+to+marry+you&qid=1596746661&sr=8-3 Deconversions: My Journey through evangelical Christianity - https://www.amazon.com/Deconversions-Journey-Through-Evangelical-Christianity/dp/0578508710 If you would like to contribute to the Conquest of Bliss, check out our patreon at patreon.com/theconquestofbliss Warning: This Podcast contains explicit language (probably), and casual conversation about what very well might be triggering topics (also probably). Listener Discretion is advised. Intro and background music mixed from public domain songs found on freemusicarchive.org This podcast was edited and produced by Kabby Productions
GNFCC North Fulton HR Forum – Pandemic: Changing People, Changing Places (“GNFCC 400 Insider,” Episode 43) How should human resources professionals re-engage their workforce as the economy reopens? What’s the current pool of available talent look like? Those question and more were addressed in this Forum. The PowerPoint deck associated with this webinar can be […] The post GNFCC North Fulton HR Forum: “Pandemic: Changing People, Changing Places” appeared first on Business RadioX ®.
Joyce Chang, JPMorgan Chair of Global Research, says she could see negative yields happening in the U.S., but doesn't see Fed policy going below zero. Matthew Harrison, Morgan Stanley Head of Biotechnology Research, says the level of antibodies that are protective for people with Covid-19 is still unknown. Megan Greene, Harvard Kennedy Senior Fellow, says the coronavirus pandemic has exposed a lot of broken aspects of the United States. Lauren Sauer, Johns Hopkins University Assistant Professor of Emergency Medicine, says we have to continue to support the W.H.O. and their role in pandemic preparedness and response. Ron Temple, Lazard Asset Management Co-Head of Multi-Asset and Head of U.S. Equity, says there needs to be more focus on the looming retirement crisis. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com
(00:00-08:59): HAPPY 1-YEAR ANNIVERSARY!! One year ago today, The Common Good took to the airwaves. Brian and Ian reflect and reminisce on their favorite moments throughout 2019. They also listen to their first show intro from a year ago. Oh how they’ve grown. (08:59-18:09): “3 Things to Do When Your Life Doesn’t Match Your Plan” writes Grant Reynolds in Relevant Magazine. Sometimes life doesn’t always go the way we think it should. Many times it goes in the exact opposite direction. Brian and Ian discuss this and how to handle uncertainty and the curveballs of life. (18:09-27:29): We are joined by Rev. Dr. Matthew Harrison, president of the Lutheran Church–Missouri Synod. He is a featured speaker at the March For Life Chicago on Saturday January 11. He talks about the sanctity of all life, especially unborn children of who the march is aiming to fight for. (27:29-36:36): “You Can’t Change Your Spouse: But you can change yourself” writes Dorothy Littell Greco in Christianity Today. Brian and Ian talk about self-reflection and growth in a marriage. How do you enter a situation without any expectations from your spouse, but expect God to move? (37:40-48:21): People magazine writes “Alex Trebek on How He Wants His Final Episode of Jeopardy! to End: I've 'Rehearsed It Already'”. Brian and Ian reflect on the illustrious career of Alex Trebek and how emotional this must be for him to leave ‘Jeopardy!’. (48:21-58:38): Bert Fulks writes in the Today Parenting Team “X-Plan: Giving your kids a way out (#xplan)”. Brian and Ian, as parents, talk about uncomfortable or even unsafe situations kids find themselves in. This strategy is useful and quick. (58:38-1:09:00): Sarah Rich writes in The Atlantic “Today’s Masculinity Is Stifling”. As boys grow up, the process of becoming men encourages them to shed the sort of intimate connections and emotional intelligence that add meaning to life. Brian and Ian touch on toxic masculinity and the development of boys in America today. (1:09:00-1:15:44): Brian and Ian’s “Weird Stuff We Found on the Internet”: Polly wants a...uh...to get out, and Charmin, TAKE MY MONEY! Tombstone Pizza comes out with new snake sausage pizza, and this town ain’t big enough for the two of us. Meanwhile, Pennsylvania needs to get it’s Walmarts together.See omnystudio.com/listener for privacy information.
We are joined by Rev. Dr. Matthew Harrison, president of the Lutheran Church–Missouri Synod. He is a featured speaker at the March For Life Chicago on Saturday January 11. He talks about the sanctity of all life, especially unborn children of who the march is aiming to fight for. The March For Life is building upon the success of the march and rally, the March for Life Chicago partnered with weDignify to present the inaugural Convention for marchers to connect and unite to protect life! The Convention offers something for many ages. From a youth rally in the morning to a banquet and dancing in the evening, you won’t want to miss this! https://www.marchforlifechicagoconvention.org/See omnystudio.com/listener for privacy information.